Eckert & Ziegler to Provide Actinium Pharmaceuticals with Actinium-225

Eckert & Ziegler SE has announced an agreement with Actinium Pharmaceuticals, Inc. to supply the radioisotope Actinium-225 (Ac-225). This supply deal will aid Actinium Pharmaceuticals in advancing its radiotherapy agent, Actimab-A, and other development candidates across U.S. and international trials. Ac-225 is noted for its potential in targeted radiotherapy due to its ability to release alpha particles that precisely target tumor cells while limiting damage to healthy tissue.

Actimab-A, which targets the CD33 receptor associated with acute myeloid leukemia (AML), is central to Actinium's efforts to develop therapies for myeloid malignancies and solid tumors. The agreement promises a steady supply of Ac-225, seen as vital in addressing a global shortage of this radioisotope.

Dr. Harald Hasselmann, CEO of Eckert & Ziegler, expressed optimism about expanding the range of indications for Ac-225. Sandesh Seth, CEO of Actinium Pharmaceuticals, highlighted the importance of this agreement in their aggressive plans to broaden their clinical pipeline in areas of unmet medical need.